CareDx (CareDx) Cash And Cash Equivalents : $82.2 Mil (As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

What is CareDx Cash And Cash Equivalents?

CareDx's quarterly cash and cash equivalents declined from Jun. 2023 ($87.79 Mil) to Sep. 2023 ($75.98 Mil) but then increased from Sep. 2023 ($75.98 Mil) to Dec. 2023 ($82.20 Mil).

CareDx's annual cash and cash equivalents declined from Dec. 2021 ($348.49 Mil) to Dec. 2022 ($89.92 Mil) and declined from Dec. 2022 ($89.92 Mil) to Dec. 2023 ($82.20 Mil).

CareDx Cash And Cash Equivalents Historical Data

The historical data trend for CareDx's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CareDx Cash And Cash Equivalents Chart

CareDx Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash And Cash Equivalents

Get a 7-Day Free Trial

38.22

134.67

348.49

89.92

82.20

CareDx Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash And Cash Equivalents	Get a 7-Day Free Trial															89.92	74.66	87.79	75.98	82.20

CareDx Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

CareDx (NAS:CDNA) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

CareDx Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of CareDx's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

CareDx (CareDx) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » CareDx Inc (NAS:CDNA) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

1K9:Germany

Address

8000 Marina Boulevard, Brisbane, CA, USA, 94005

Website

https://www.caredx.com

CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre-and post-transplant patient journey and is a provider of genomics-based information for transplant patients. Its primary operations are in Brisbane, California; Omaha, Nebraska; Fremantle, Australia and Stockholm, Sweden.

Executives

Reginald Seeto	officer: See Remarks	C/O ARDELYX, INC., 34175 ARDENWOOD BLVD, SUITE 200, FREMONT CA 94555
Peter Maag	director, officer: President and CEO	CAREDX, INC., 3260 BAYSHORE BOULEVARD, BRISBANE CA 94005
Abraham Ronai	officer: See Remarks	C/O CAREDX, INC., 8000 MARINA BLVD, BRISBANE CA 94005
Grace Colon	director	C/O CAREDX, INC., 3260 BAYSHORE BOULEVARD, BRISBANE CA 94005
Abhishek Jain	officer: See Remarks	C/O CAREDX, INC., 1 TOWER PLACE, 9TH FLOOR, SOUTH SAN FRANCISCO CA 94080
Michael Goldberg	director	3000 SAND HILL ROAD, BUILDING 3, SUITE 290, MENLO PARK CA 94025
George Bickerstaff	director	C/O VION PHARMACEUTICALS, INC., 4 SCIENCE PARK, NEW HAVEN CT 06511
Ankur Dhingra	officer: Chief Financial Officer	C/O CAREDX, INC., 1 TOWER PLACE, 9TH FLOOR, SOUTH SAN FRANCISCO CA 94080
Arthur A Torres	director	87 BVENA VISTA TERRACE, SAN FRANCISCO CA 94117
Alexander L Johnson	officer: Chief Business Officer	C/O DIADEXUS, INC., 349 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Hannah Valantine	director	1305 O'BRIEN DRIVE, MENLO PARK CA 94025
Sasha King	officer: Chief Commercial Officer	C/O CAREDX, INC., 3260 BAYSHORE BOULEVARD, BRISBANE CA 94005
William A Hagstrom	director	320 WAKARA WAY, SALT LAKE CITY UT 84108
Ralph Snyderman	director	C/O SAIC, 10260 CAMPUS POINT DR M/S F3, SAN DIEGO CA 92121
Marcel Konrad	officer: See Remarks	C/O CAREDX, INC., 1 TOWER PLACE, 9TH FLOOR, SOUTH SAN FRANCISCO CA 94080